Program
AB-001
Also written as “AB001” and “AB001 patch”.
Its studies are mostly in Low Back Pain · Prostatic Neoplasms, led by 2 companies.
Furthest: phase 2, since Apr 30, 20153 company-led studies, 1 open or runningNext primary completion: Nov 3, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Frontier Biotechnologies | 20 open or running | phase 2since Apr 30, 2015 | Apr 30, 2015 | none ahead |
| ARTBIO | 11 open or running | phase 1since Jul 21, 2025 | Jul 21, 2025 | Nov 3, 2027phase 1 · NCT07214961 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 30, 2015First study: phase 2 study in Chronic Low Back PainNew to Frontier BiotechnologiesFrontier Biotechnologies · NCT02436824 · 146 enrolled · United States
- Jun 19, 2019Phase 1 study in Chronic Low Back PainFrontier Biotechnologies · NCT03997734 · 34 enrolled · China
- Jul 21, 2025ARTBIO's first study: phase 1 study in Prostatic NeoplasmsNew to ARTBIOARTBIO · NCT07214961 · 80 enrolled · United States
Ahead
- Nov 3, 2027Primary completion: phase 1 study in Prostatic NeoplasmsARTBIO · NCT07214961
TargetBeta
FOLH1 →read by rule
“This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who are either 177Lu-PSMA naïve or experienced.”study text, by rule · the study
Other programs on FOLH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| flotufolastat F 18rule | Bracco | phase 4 | 7 |
| piflufolastatrule | Lantheus | phase 4 | 5 |
| abefolastat tesaroxetan CU-64rule | clarity-pharmaceuticals-ltd | phase 3 | 5 |
| gallium 68 PSMA-11rule | Novartis | phase 3 | 4 |
| Lutetium Lu 177 Ludotadipeprule | futurechem | phase 3 | 3 |
| Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 | Johnson & Johnson | phase 3 | 2 |
| Lutetium Lu 177 NYM032rule | Norroy Bioscience | phase 3 | 2 |
| actinium AC-225 vipivotide tetraxetan | Novartis | phase 3 | 2 |
| HRS-4357 | Jiangsu HengRui Medicine | phase 3 | 2 |
| zadavotide guraxetan | AstraZeneca | phase 2 | 4 |
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 2 |
| SHR-4394 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07214961Prostatic Neoplasms · United States | 1 | Active, not recruiting | ARTBIO | Nov 3, 2027 | 80 |
| NCT03997734Chronic Low Back Pain · China | 1 | Completed | Frontier Biotechnologies | Nov 11, 2019 | 34 |
| NCT02436824Chronic Low Back Pain · United States | 2 | Completed | Frontier Biotechnologies | Jul 2015 | 146 |
How it is read
Names in the registry
- “AB001”, 2 entries
- “AB001 patch”, 1 entry
Conditions, from the studies’ own filings
- Low Back Pain, 2 studies
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.